Legend Biotech Corporation
LEGN
ISIN null / Valor 54834759
Legend Biotech Corporation
UMushroom community rating:
About company
Legend Biotech Corporation is a biotechnology company focused on developing investigational agents and innovative technologies in personalized medicine, with a particular emphasis on cell therapies for treating hematological malignancies and solid tumors. The company is dedicated to exploring the potential of cell therapies to address diseases that are considered intractable and incurable. Through its pipeline of cutting-edge therapies, Legend Biotech aims to provide new treatment options for patients with challenging medical conditions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (18.11.2025):
Legend Biotech Corporation's Third Quarter 2025 results demonstrate significant progress across revenue, expenses, and clinical milestones. The report highlights a robust increase in collaboration revenue, improved net loss figures, and strong cash reserves, alongside key regulatory and operational advancements supporting the growth of their flagship product, CARVYKTI®.
Revenue Performance
Collaboration revenue rose to $261.8 million in Q3 2025 from $142.8 million in Q3 2024, while license revenue decreased to $10.5 million compared to $17.1 million the prior year, reflecting differences in timing of trial-related activities.
Expense and Profitability
Research and development expenses increased to $113.1 million, with selling and distribution expenses climbing to $52.6 million. These changes, coupled with relatively stable administrative costs, contributed to an improved net loss of $39.7 million (down from $125.3 million) and an adjusted net loss of $18.8 million.
Clinical and Regulatory Updates
The report underscores key advances for CARVYKTI®: both U.S. FDA and European Commission updated the label to reflect overall survival benefits, and over 9,000 patients have now been treated. Additionally, the initiation of the CARTITUDE-10 trial marks further clinical exploration of the therapy.
Financial Position and Outlook
Legend Biotech ended the quarter with approximately $1.0 billion in cash, cash equivalents, and time deposits, positioning the company strongly for operational expansion and anticipated profitability beyond 2026.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5485 M
Market cap (USD)
1,305,484
Daily traded volume (Shares)
32.9 / 32.18
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Adam Hrehovcik
Julia Tian
Mike Panichella
EQUITIES OF THE SAME SECTOR
